Trials / Completed
CompletedNCT00924534
A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes
A Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients With Type 2 Diabetes on Metformin Monotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Abbott Products · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo |
| DRUG | SLV337 | SLV337 400 mg/day |
| DRUG | SLV337 | SLV337 800 mg/day |
| DRUG | SLV337 | SLV337 1400 mg/day |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2009-06-19
- Last updated
- 2012-01-04
Locations
12 sites across 3 countries: Bulgaria, Poland, South Africa
Source: ClinicalTrials.gov record NCT00924534. Inclusion in this directory is not an endorsement.